Development and characterization of viral inhibition assay (VIA) : a CD8T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates

We have characterized an assay measuring CD8+ T cell-mediated inhibition of human immunodeficiency virus (HIV) type 1 replication, demonstrating specificity and reproducibility and employing a panel of HIV -1 isolates. The assay uses relatively simple autologous cell culture and enzyme-linked immuno...

Full description

Bibliographic Details
Main Author: Spentzou, Aggeliki
Published: University of London 2012
Subjects:
Online Access:http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.577536
id ndltd-bl.uk-oai-ethos.bl.uk-577536
record_format oai_dc
spelling ndltd-bl.uk-oai-ethos.bl.uk-5775362015-03-20T05:38:40ZDevelopment and characterization of viral inhibition assay (VIA) : a CD8T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidatesSpentzou, Aggeliki2012We have characterized an assay measuring CD8+ T cell-mediated inhibition of human immunodeficiency virus (HIV) type 1 replication, demonstrating specificity and reproducibility and employing a panel of HIV -1 isolates. The assay uses relatively simple autologous cell culture and enzyme-linked immunosorbent assay (ELlSA), avoids generation of T cell clones and can be performed with <2 million peripheral blood mononuclear cells. Efficient CD8+ T cell-mediated cross-clade inhibition of HIV-I replication in vitro was demonstrated in antiretroviral therapy-naive HIV -l-infected subjects with controlled viral replication in vivo but not in viremic subjects. The observed HIV-I inhibition is reversed by blockade of MHC I and physical separation of effector CD8+ and target CD4+ T cells by transwell chambers. An HIV-I vaccine candidate, consisting of adenovirus (Ad) serotype 35 vectors tested in a phase I clinical trial, induced CD8+ T cells that efficiently inhibited HIV -1. Assessment of direct antiviral T cell function by this assay provides additional information to guide vaccine design and the prioritizing of candidates for further clinical trials. 2616.979201University of Londonhttp://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.577536Electronic Thesis or Dissertation
collection NDLTD
sources NDLTD
topic 616.979201
spellingShingle 616.979201
Spentzou, Aggeliki
Development and characterization of viral inhibition assay (VIA) : a CD8T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates
description We have characterized an assay measuring CD8+ T cell-mediated inhibition of human immunodeficiency virus (HIV) type 1 replication, demonstrating specificity and reproducibility and employing a panel of HIV -1 isolates. The assay uses relatively simple autologous cell culture and enzyme-linked immunosorbent assay (ELlSA), avoids generation of T cell clones and can be performed with <2 million peripheral blood mononuclear cells. Efficient CD8+ T cell-mediated cross-clade inhibition of HIV-I replication in vitro was demonstrated in antiretroviral therapy-naive HIV -l-infected subjects with controlled viral replication in vivo but not in viremic subjects. The observed HIV-I inhibition is reversed by blockade of MHC I and physical separation of effector CD8+ and target CD4+ T cells by transwell chambers. An HIV-I vaccine candidate, consisting of adenovirus (Ad) serotype 35 vectors tested in a phase I clinical trial, induced CD8+ T cells that efficiently inhibited HIV -1. Assessment of direct antiviral T cell function by this assay provides additional information to guide vaccine design and the prioritizing of candidates for further clinical trials. 2
author Spentzou, Aggeliki
author_facet Spentzou, Aggeliki
author_sort Spentzou, Aggeliki
title Development and characterization of viral inhibition assay (VIA) : a CD8T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates
title_short Development and characterization of viral inhibition assay (VIA) : a CD8T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates
title_full Development and characterization of viral inhibition assay (VIA) : a CD8T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates
title_fullStr Development and characterization of viral inhibition assay (VIA) : a CD8T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates
title_full_unstemmed Development and characterization of viral inhibition assay (VIA) : a CD8T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates
title_sort development and characterization of viral inhibition assay (via) : a cd8t cell neutralization assay for use in clinical trials of hiv-1 vaccine candidates
publisher University of London
publishDate 2012
url http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.577536
work_keys_str_mv AT spentzouaggeliki developmentandcharacterizationofviralinhibitionassayviaacd8tcellneutralizationassayforuseinclinicaltrialsofhiv1vaccinecandidates
_version_ 1716793408935165952